Basit öğe kaydını göster

dc.contributor.authorOzyilkan, Ozgur
dc.contributor.authorYalcin, Suayib
dc.contributor.authorYildiz, Ramazan
dc.contributor.authorDane, Faysal
dc.contributor.authorKaraoglu, Aziz
dc.contributor.authorOksuzoglu, Berna
dc.contributor.authorSevinc, Alper
dc.contributor.authorOzdemir, Feyyaz
dc.contributor.authorTurna, Hande
dc.contributor.authorUslu, Ruchan
dc.contributor.authorUlay, Esat
dc.date.accessioned2019-05-25T14:14:07Z
dc.date.available2019-05-25T14:14:07Z
dc.date.issued2018
dc.identifier.issn1178-6930
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843136/
dc.identifier.urihttp://hdl.handle.net/11727/3302
dc.description.abstractIntroduction: The introduction of targeted therapies in renal cell carcinoma has significantly improved its prognosis and treatment outcomes in recent years. Such treatment options are targeted therapies of the vascular endothelial growth factor (VEGF) pathway and the mammalian target of the rapamycin pathway. With the use of tyrosine kinase inhibitors (TKIs) and mammalian target of the rapamycin inhibitors, overall survival has increased up to 2 years. In Turkey, due to applicable reimbursement conditions for patients with metastatic renal cell carcinoma (mRCC), interferon use is mandated as a first-line treatment, thus providing information on the use of everolimus only after initial interferon and second-line VEGF-targeted treatments such as VEGF-TKI. Patients and methods: To provide a first real-life data set in Turkey, we conducted a prospective, non-interventional, observational study and assessed the efficacy and safety of everolimus after two lines of treatment including interferon. A total of 100 patients with histologically confirmed mRCC were enrolled in the study from 11 centers between June 2012 and March 2014 (70 males and 30 females). Efficacy was assessed on the basis of progression-free survival and overall survival; safety of everolimus was assessed on the basis of adverse event occurrence. Results: The study results showed that the median progression-free survival with everolimus treatment was 8.1 months (95% CI: 5.1-11.1) and the median overall survival was 17.6 months (95% CI: 10.1-25.1), thus indicating a better overall response based on survival durations than those from the randomized Phase III REnal Cell cancer treatment with Oral RAD001 given Daily study results (4.9 and 14.8 months, respectively). Conclusion: The study showed that everolimus treatment is a safe and effective treatment option in the treatment of mRCC after VEGF-TKI, with an acceptable safety and tolerability profile in real-life settings.en_US
dc.language.isoengen_US
dc.relation.isversionof10.2147/OTT.S148917en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMetastatic renal cell carcinomaen_US
dc.subjectmTOR inhibitorsen_US
dc.subjectEverolimusen_US
dc.subjectObservational studyen_US
dc.subjectReal-life settingen_US
dc.subjectTreatment patternsen_US
dc.titleA national, multicenter, non-interventional, observational study on treatment patterns in patients with metastatic renal cell carcinoma in Turkey - NOTES studyen_US
dc.typearticleen_US
dc.relation.journalONCOTARGETS AND THERAPYen_US
dc.identifier.volume11en_US
dc.identifier.startpage1223en_US
dc.identifier.endpage1228en_US
dc.identifier.wos000427407200003en_US
dc.identifier.scopus2-s2.0-85044197512en_US
dc.contributor.pubmedID29551901en_US
dc.contributor.orcID0000-0001-8825-4918en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.contributor.researcherIDAAD-2817-2021en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster